DTX-P7 is a peptide-drug conjugate (PDC). DTX-P7, composed of Docetaxel (DTX) and a heptapeptide (P7), induces the unfolded protein response and subsequent apoptosis by degrading Hsp90.

Physicochemical Properties

Molecular Formula	C84H118N8O25
Molecular Weight	1639.87
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	DTX-P7 inhibited membrane Hsp90 expression in a dose- and time-dependent manner, while no changes were observed at the mRNA level [1]. DTX-P7 enhanced the phosphorylation of PERK and eIF2α, but no changes in XBP-1 mRNA splicing were observed in A549 cells exposed to DTX-P7 [1].
ln Vivo	DTX-P7 (mice implanted with A549 xenograft tumor, 15/30 mg/kg, once a week for 4 weeks) inhibited tumor growth of dormant/slowly proliferating A549/CD133 + cells by degrading DYRK1A and subsequently enabling cell cycle reentry [1].
References	[1]. DTX-P7, a peptide-drug conjugate, is highly effective for non-small cell lung cancer. J Hematol Oncol. 2022 Jun 3;15(1):73.

Solubility Data

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	0.6098 mL	3.0490 mL	6.0980 mL
	5 mM	0.1220 mL	0.6098 mL	1.2196 mL
	10 mM	0.0610 mL	0.3049 mL	0.6098 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.